Clinical trials: Tauopathies
Alzheimer Disease, Dementia
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05522387
- Testing
- XPro1595
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- Inmune Bio, Inc.
Tauopathies
CW2IP2: Imaging and Diagnostic Assessments
This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at…
- Trial name
- NCT06083467
- Testing
- Brain MRI Scan, Neurologic exam
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer Disease, Mild Cognitive Impairment
Validation of Blood Biomarkers for Alzheimer's Disease
Alzheimer's disease (AD) has gradually become one of the major global public health issues due to its prevalence, which increases with age and life expectancy, and the economic cost of caring for patients whose cognitive decline…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Tauopathies
- Trial name
- ALZAN (NCT05427448)
- Testing
- Measurement of amyloid and pTau blood biomarkers
- Where
- 3 sites in France
- Volunteers
- 342 people
- Sponsor
- University Hospital, Montpellier
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain…
- Trial name
- NCT06932809
- Testing
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Pennsylvania
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with…
- Trial name
- NCT06032026
- Testing
- 11C-HY-2-15 PET, brain MRI, Amyloid PET scan
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease, Cognitive Impairment
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with…
- Conditions
- Alzheimer's Disease, Cognitive Impairment, Tauopathies, Mild Cognitive Impairment
- Trial name
- NCT04445831
- Testing
- ACI-35.030, JACI-35.054
- Where
- 9 sites in Finland, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- AC Immune SA
Alzheimer Disease, Dementia
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
This cluster randomized pragmatic clinical trial will test the effectiveness and feasibility of embedding the Tele-Savvy intervention, a psychoeducational program for family and other informal caregivers of older adults living in…
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05080777
- Testing
- Tele-Savvy, Caregiving During Crisis (Educational Program)
- Where
- 2 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- UConn Health
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Tau Distributions in Patients With Tauopathy Using APN-1607 PET Scan
Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The diagnosis of PD is primarily based on clinical presentations while the pathology stage of a-synuclein containing Lewy body deposition has already…
- Trial name
- NCT04557865
- Testing
- 18F-PMPBB3 (APN-1607) PET imaging
- Where
- Taiwan
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Alzheimer Disease
F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)
The purpose of this research study is to evaluate tau distribution in the brain of subjects with: FTD caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic…
- Trial name
- NCT02707978
- Testing
- F 18 T807
- Where
- United States
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Alzheimer's Disease, Brain Diseases
CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests.
- Conditions
- Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT03938870
- Testing
- L-Leucine 13C6
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Dementia
Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
There is a need for caregiver-initiated and -implemented non-pharmacological interventions directly to and for the person with dementia, including environmental assessment and modification, as first-line treatments for behavioral…
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05202223
- Testing
- Harmony at HOME (H@H)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Elizabeth K Rhodus
Alzheimer Disease
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies.
- Trial name
- ALZ-NET (NCT06170268)
- Testing
- Routine Care Documentation
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Alzheimer's Disease and Related Disorders Association, Inc
Alzheimer's Disease, Mild Cognitive Impairment
Nicotinamide as an Early Alzheimer's Disease Treatment
The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in…
- Trial name
- NEAT (NCT03061474)
- Testing
- Nicotinamide
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of California, Irvine
Mild Cognitive Impairment (MCI), Alzheimer Disease
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases
- Trial name
- NCT05321498
- Testing
- XPro1595
- Sponsor
- Inmune Bio, Inc.
Cognitively Normal, Mild Cognitive Impairment
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and…
- Conditions
- Cognitively Normal, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT03903211
- Testing
- [18F]PI-2620
- Where
- South Korea
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Jae Seung Kim
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.
Healthy Volunteers, Tauopathies
A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
This is a Phase 1, first-in-human (FIH), double-blinded, placebo-controlled study where healthy subjects are randomly allocated to receive APNmAb005 or placebo.
- Conditions
- Healthy Volunteers, Tauopathies, Alzheimer Disease
- Trial name
- NCT05344989
- Testing
- APNmAb005
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics, LLC
Alzheimer Disease
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans
The purpose of this research study is to evaluate a new radioactive compound used in positron emission tomography (PET) scans in identifying tau tangles (a certain protein that might be associated with Alzheimer's disease) in the…
- Trial name
- ADRCproj1 (NCT03287765)
- Testing
- 18F-AV-1451
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).
- Trial name
- NCT05532358
- Testing
- anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH